# 1. Financial Performance ## A. Key Figures * **Consolidated Revenue:** **₹6,860 Cr** (Q3 FY26) (+30% YoY) * EBITDA: ₹18.2 Bn (Q3 FY26) (+31% YoY) · Margin: 26.5% (Q3) (+20 bps YoY) · 9M Margin: 30.3% * **Adjusted Net Profit:** **₹1,110 Cr** (Q3 FY26) (+9% YoY) * **Net Debt:** **₹3,000 Cr** (post-acquisitions, deemed comfortable) ## B. Revenue Growth * **Sustained Core Momentum:** Base business delivered strong double-digit growth excluding acquisitions, underpinning robust topline expansion. * **Emerging Contributions:** Bio CDMO segment expected to contribute over **₹10 Cr**, signaling early-stage commercial traction. * **Leadership Confidence:** Management characterizes 2025 as a transformative year marked by exceptional growth and disciplined profitability. ## C. EBITDA Margin * **Margin Expansion Achieved:** Q3 EBITDA margin improved 20 bps YoY to 25.5%, reflecting operational efficiency despite R&D lumpiness. * **Strong Forward Outlook:** Q4 margin guidance held at **23% or higher**, even without Lenalidomide revenue, indicating resilient underlying profitability. * **R&D Investment Ramping:** FY26 R&D expected to reach **5%–8% of revenue**, driven by biologics trials and seasonal spend concentration. * **Cost Pressures Ahead:** Higher finance costs anticipated in FY27+ due to current debt and cash structure. ## D. Balance Sheet * **Controlled OpEx Run Rate:** Non-R&D operating expenses stabilized at **₹1,750–₹1,800 Cr/quarter**, inclusive of recent acquisitions. * **Excluded Costs Identified:** Agenus-related costs (~**₹2 Cr/year**) and Saro launch expenses (commercialization, MR) are incremental to current run rate. * **Acquisition-Funded Leverage:** Net debt of ₹3,000 Cr reflects strategic M&A activity; management maintains position is within comfort zone. --- # 2. Product & Therapy Performance ## A. Key Figures * Consumer Wellness Revenue: ₹9.6 billion (+113% YoY) · chronic portfolio at 45.3% of total business (+560 bps over 3 years) * **Volume Growth:** **11%** in generics · **double-digit** in Consumer Wellness (ex-acquisition) * **Portfolio Growth:** **>23%** in innovative portfolio · **>13%** in growth booster brands * **Saro Franchise:** **>₹450 Cr** annualized run rate ## B. Specialty Launches * **First 505(b)(2) Entry:** BEIZRAY launch marks Zydus’s strategic entry into U.S. oncology specialty, expanding high-value product footprint. * **Differentiated GLP-1 Strategy:** Zydus to launch novel Semaglutide formulation in India with **single-device dose escalation**, reducing patient burden and supply chain complexity. * **First-Mover in Rare Disease:** Zycubo approved and launched as first-ever therapy for Menkes disease, establishing Sentynl as a **3-product rare disease player** with BD&L pipeline potential. * **C. S. Specialty Momentum:** Sentynl’s Zycubo launch sets foundation for strong U.S. specialty growth, supported by robust innovation pipeline. ## C. Generics Portfolio * **Market Outperformance:** Generics business leads in key segments including **Oncology, Cardiology, and Respiratory**, with strong volume growth despite competitive pressures. * **Robust Filing Activity:** 18 ANDAs filed, 8 approvals secured, and 4 new launches executed in the quarter, reflecting sustained regulatory momentum. * **Strategic First-to-File Pipeline:** One of the strongest years for exclusive first-to-file filings (4–5 sole opportunities), despite Empagliflozin not being a sole FTF. * **Portfolio Transition Complete:** Revlimid contribution has fully wound down with no expected revenue next quarter, marking clean exit from legacy product. ## D. Rare Disease & Diagnostics * **Rare Disease Platform Validated:** Zycubo’s approval and launch confirm Sentynl’s capability in ultra-rare diseases, enabling **1–2 annual BD&L deals**. * **Oncology Ecosystem Expansion:** CanAssist and liquid biopsy offerings strengthen Zydus’s position as **India’s largest oncology player** by integrating diagnostics with therapeutics. ## E. Biosimilars Progress * **Ranibizumab Launch Imminent:** Biosimilar expected in H2, targeting unmet supply gap; commercialized via existing 505(b)(2) field force. * **Biologics Traction Building:** Desi and broader biologics portfolio showing **strong growth and increasing market adoption**, contributing to long-term innovation engine. --- # 3. Geography & Market Mix ## A. Key Figures * North America Revenue: **₹28 Bn** (pharmaceuticals, +16% YoY) * **International Formulations Revenue:** **₹790 Cr** (+38% YoY, YTD +38%) ## B. North America * **Resilient US Generics Growth:** Business on strong trajectory despite upcoming Revlimid loss, with volume growth significantly outpacing market. * **Strategic Shift to Specialty:** Portfolio diversification into specialty therapies underway to sustain long-term growth momentum. * **Canada Pipeline Activity:** Active regulatory momentum with **5 ANDA filings**, **4 approvals**, and **1 product launch** in the quarter. ## C. India Business * **Market-Leading Growth:** Branded formulations outpace market for consecutive quarter, driven by innovation and pillar brands. * **Chronic & Novel Product Momentum:** Accelerated growth in chronic therapies, led by **Saroglitazar**, **Desidustat**, and biosimilars, with Desidustat showing notable step-up. * **Multi-Year Double-Digit Outlook:** Growth outlook sustained by innovative pipeline, including **GLP-1s**, **Sema**, and first-in-class assets, though delayed entry on initial GLP-1 wave. ## D. Emerging Markets * **Explosive International Expansion:** Formulations business nearly tripled in 4–5 years, driven by branded strategy in emerging markets via CVS, led by CNS and expanding into metabolic and pain. * **Diversified Growth Engines:** Strong double-digit growth across emerging markets and Europe, supported by therapy-led localization and expanded portfolio reach. * **Global Vaccine Tenders Secured:** Won supply contracts for **rabies vaccine (PAHO, Latin America)** and **typhoid conjugate vaccine (UNICEF, LMICs)**. * **Wellness & Geographic Expansion:** WeightWorld and Comfort Click launched in **Poland, Finland, and Portugal**, tapping high-growth wellness segments. ## E. Europe Performance * **Europe Recovery Accelerating:** After three years of headwinds, business shows meaningful improvement in market reach and portfolio contribution. --- # 4. R&D & Pipeline Progress ## A. Key Figures * **MR Tender Win:** **₹100+ Cr** opportunity realized in Indian public market * **Vaccine Milestones:** **CE mark approval** secured for Andy robotic surgical system; **pre-qualification** achieved for rabies vaccine ## B. Clinical Trials * **Phase III Greenlight:** Regulatory approval obtained in India to initiate **Phase III trials** for second biosimilar ADC, marking a significant advancement in the oncology pipeline. * **Progress Across Indications:** Phase II trial underway for Bivalent Typhoid Conjugate vaccine, while **Phase 1 readout for Keytruda biosimilar expected in 2024**, setting stage for future BLA. ## C. Regulatory Filings * **D. S. Market Push:** Pivotal NDA filing for Saroglitazar in the U.S. upcoming, with **U.S. FDA submission planned for PBC indication this quarter**, reinforcing specialty pharma ambitions. * **Global Manufacturing Strategy:** Initial BLA for Keytruda biosimilar to be filed based on **Formycon’s European facility**, with **Agenus’s U.S. facility under evaluation as second source**. ## D. 505(b)(2) Pipeline * **E. S. Growth Engine:** Expansion of **505(b)(2) franchise** in liquids and supportive oncology driving U.S. growth, with **BEIZRAY commercialized** and another product **expected to file soon**, potentially launching within a year. * **Specialty Launch Platform:** Biosimilar **ranibizumab** positioned as a **U.S. specialty launch**, enhancing footprint in high-value therapeutic areas. ## E. Vaccine Development * **Public & Private Momentum:** FY'26 MR tender win captures immediate value, while **flu vaccine gaining meaningful share** with ambition to become **India’s leading player**. * **Global Access Enabled:** Rabies vaccine **pre-qualification unlocks global tenders**, with revenue scaling anticipated in **second and third years of supply**. --- # 5. M&A & Strategic Partnerships ## A. Recent Acquisitions * **Strategic Portfolio Expansion:** Disciplined M&A has activated new growth engines, with successful integration of Amplitude Surgical, Comfort Click, and WeightWorld, enhancing scale in medical devices and digital wellness. * **Comfort Click Strengthens Global Wellness Play:** Acquisition establishes leadership in digital wellness with dual-market reach in India and Europe, though it carries **lower margins** than core business, potentially weighing on blended performance. * **Amplitude Surgical Margin-Neutral:** Contribution from Amplitude is margin-neutral given alignment with current company levels, supporting earnings stability post-acquisition. * **US & Specialty M&A Focus:** Inorganic growth strategy in the US targets specialty-driven assets aligned with commercial capabilities; future Saroglitazar expansion will focus on **liver hepatogastro** and niche adjacencies. * **Higher OPEX Driven by Acquisitions:** Elevated operating expenses are primarily due to recent M&A activity, not incremental field force or marketing spend. ## B. Licensing Deals * **Biosimilar Milestones Achieved:** Licensing of **Pembrolizumab and Ranibizumab** marks major progress in US biosimilars, supported by US biologics facility utilization and supply partnerships (e.g., Agenus). * **505(b)(2) Pipeline Advancement:** Exclusive license for a sterile supportive oncology product targets **NDA filing in 2026**, with a second product to follow, expanding specialty footprint. * **Ranibizumab Launch Imminent:** Biosimilar launch expected in **2H of current year**, bolstering near-term specialty portfolio growth. ## C. Diagnostic Alliances * **Precision Oncology Capabilities Enhanced:** Collaboration with **Myriad Genetics** introduces three advanced diagnostic tests (MyChoice, MyRisk, Prolaris), significantly strengthening India’s liquid biopsy and genetic testing ecosystem. * **Multi-Year Growth Catalyst:** Partnership aims to build a **sticky, high-growth diagnostics business** over the next **2–3 years**, expanding patient access and leveraging existing Guardant alliance success. ## D. Commercial Collaborations * **CDMO Monetization Pathway:** Agenus deal to kick off **H2 FY27** with BOT/BAL supply, marking commercialization of CDMO business post-qualifications. * **First-Mover Biosimilar Opportunity:** Keytruda biosimilar is **furthest along in development** with advanced FDA feedback, positioning Zydus for a **potential first-to-file** advantage. * **Strategic Co-Promotion Model:** Zydus to enable **2–3 partners** to launch products via its Sema platform in India, broadening market reach without direct commercial burden. * **Formycon Alliance for Ranibizumab:** Partnership with Formycon supports development and commercialization of the Ranibizumab biosimilar, de-risking execution. --- # 6. Pricing & Regulatory Risks ## A. Patent Expirations * **Patent Risk Horizon:** Peak sales potential for Saroglitazar and Desidustat remains undisclosed; patent-related risks over the **3–4 year** outlook acknowledged but not specified. ## B. USFDA Inspections * **Mixed Inspection Outcomes:** Injectable facility at Jarod received an **EIR with voluntary action indicated** status post-August 2025 pre-approval inspection. * **Positive Regulatory Signal:** Oral solid dosage facility in Ahmedabad SEZ (SEZ II) secured **EIR with no action indicated** following September 2025 inspection. ## C. Litigation Exposure * **Mirabegron Trial Underway:** US trial commenced February 9 with jury selection; case presentations began February 10, with court-mandated mediation ongoing. * **Litigation Status Unclear:** Despite reports of a Lupin settlement, company refrains from commenting on competitive implications until trial or mediation concludes. ## D. Market Competition * **Moderate Price Pressure:** Generic price erosion expected in the **single digits**, excluding high-impact products such as **Lenalidomide**. * **Ranibizumab Market Shift:** Sandoz exited after holding ~**48% market share**, though reasons—regulatory or commercial—remain unknown to management. --- # 7. Guidance & Outlook ## A. Key Figures * **Revenue Growth Outlook:** **>20%** sustainable growth expected near-term * **Q4 EBITDA Margin Guidance:** **23%+** despite higher R&D and acquisition-related blend * **Product Launch Plan:** **40–45+** products targeted in FY'27, including **4–5 sizable/exclusive** launches * **Vaccines Revenue Target:** **>₹1,000 Cr** within 3–4 years * **QIP Fundraising:** **₹5,000 Cr** approved, timing market-dependent to minimize dilution ## B. Revenue Forecast * **New CDMO Revenue Inflection:** Agenus-related CDMO revenue expected to commence in **H2 FY27**, scaling over a 3–4 year horizon. * **Growth Drivers:** Sustainable >20% revenue growth underpinned by operational execution and expansion momentum. ## C. Margin Expectations * **Near-Term Margin Resilience:** Q4 EBITDA margin guided at 23%+ despite elevated R&D and dilutive impact from recent acquisitions. * **Limited Forward Margin Clarity:** No EBITDA margin guidance for next fiscal; updated outlook expected at start of FY'27. ## D. Launch Pipeline * **CDMO Scale-Up Pathway:** CDMO business poised for meaningful growth over 2–3 years, driven by clinical progress of **BOT, BAL** and new project wins, with strong European traction. * **Key Biosimilar Timelines:** Keytruda biosimilar launch aligned with 2028–2029 patent expiries; Palbociclib timing hinges on pediatric exclusivity decision—**FY'27** (if denied) or **FY'28** (if granted). * **Robust Product Launch Cadence:** 40–45+ launches planned in FY'27, including multiple high-value and exclusive products, to fuel multi-year growth. * **Strategic Pipeline Confidence:** First-to-file wins and settlements reinforcing confidence in future growth pipeline. ## E. Funding Plans * **Capital Allocation Discipline:** ₹5,000 Cr QIP remains on hold—timing market-sensitive; no near-term need given self-funding capacity from internal accruals. * **Saro Cost Phasing:** Major Saro-related expenses expected in **FY28**, with gradual ramp-up tied to filings, hiring, and strategic execution; clearer cost view by Q4.